Reshaping U.S. and Global Drug Pricing: What Pharma Needs to Know about MFN and tariffs in 2025
In an effort to combat the high prices for prescription drugs in the U.S., the
In an effort to combat the high prices for prescription drugs in the U.S., the
Many biotech executives we currently meet report difficulties in securing their next financing round to
What is DiGA in short? DiGA, short for Digitale Gesundheitsanwendungen, translates to Digital Health Applications
The U.S. pharmaceutical landscape is set for another major shift. On May 12th, President Trump
France’s Reimbursed Early Access Programs (EAP) provide opportunities for reimbursement of new and innovative drugs
January 12th marked the launch of Joint Clinical Assessment (JCA), a key milestone in the